Only three biomed firms will be in Tel Aviv's 125-company stock index, including Alpha Tau.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, TASE: דרטס) will be added to the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE) on Nov. 5, 2026. The company, which develops cancer therapy Alpha DaRT, expects increased visibility and liquidity. Its shares are dual-listed on Nasdaq and TASE.
How this was made
The 30-second read
Why it matters
The index addition is expected to increase demand from passive funds and improve share liquidity, potentially supporting the price.
Market read
A small‑cap biotech gains index inclusion, which can attract institutional capital and modestly lift its valuation.
What to watch
Alpha Tau's clinical progress and financing needs remain uncertain, which could offset liquidity gains.
Background
Alpha Tau Medical is a dual‑listed Israeli oncology company developing Alpha DaRT therapy. Index funds tracking TA-90/TA-125 will now hold its shares.
Ticker impact
Alpha Tau Medical's shares will be added to the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange effective Nov. 5, 2026, increasing visibility and likely liquidity.
likely modest upside as institutional investors add the stock to index‑tracking portfolios
Index inclusion directly drives fund flows; the announcement is new and material for a small‑cap biotech.
Market effects
Highlights growing representation of biomed firms in Israeli benchmarks, may encourage similar listings.
Adds a biotech component to TA-90/TA-125, potentially modestly lifting the sector weight.
Limited to Israeli investors; global impact minimal.
Counterpoint
If the market has already priced the inclusion, the stock may see little upside.
Key entities
- CompanyAlpha Tau Medical Ltd.
Israeli biotech developing Alpha DaRT cancer therapy.
- ExchangeTel Aviv Stock Exchange (TASE)
Operator of the TA-90 and TA-125 indices.
